Jagsonpal Pharmaceuticals Share Price
242.40-0.62 (-0.26%)
-2.38% past 1 Year
News
Jagsonpal Pharma Q1 EBITDA rises year-on-year with margin expansion
Equity
JAGSNPHARM
Jagsonpal Pharma Q1 revenue rises year on year, driven by core operations
Equity
JAGSNPHARM
Jagsonpal Pharma posts higher Q1 standalone net profit year on year
Equity
JAGSNPHARM
Jagsonpal Pharma acquires majority stake in Aequitas Healthcare, makes it subsidiary
Equity
JAGSNPHARM
Jagsonpal Pharma to acquire 85 percent stake in Aequitas Healthcare
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals to acquire 85 percent stake in Aequitas Healthcare
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals informs about allotment of equity shares under ESOP
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals Board Recommends Dividend of Rs 4 Per Equity Share.
Equity
JAGSNPHARM
Jagsonpal Pharma Reports Strong Q4 EBITDA Growth of 27.6% YoY to Rs 11.10 Crores.
Equity
JAGSNPHARM
Jagsonpal Pharma Q4 FY Results: Net Profit Up 33% YoY to Rs 8.80 Crores, Revenue Rises 10% to Rs 64.20 Crores.
Equity
JAGSNPHARM
Jagsonpal Pharma reports Profit after tax of 8.76 Crores, in the March 2026 quarter
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals submits voting results of postal ballot
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals informs about press release
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals informs about board meeting
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals Board Approves Buyback of 16 Lakh Shares at Rs 250 Each via Tender Route.
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals informs about allotment of equity shares
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals: New Labor Code Minimal Impact on Employee Costs Post Q3 One-Time INR 2.1 Crore Provision.
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals Management Expects RPM Growth Normalization and Improved Performance Ahead.
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals Maintains 15% FY26 Guidance; Q1 Growth Driven by Yesharma Acquisition
Equity
JAGSNPHARM
Jagsonpal Pharmaceuticals Targets 50% Growth From Price Increases and New Products
Equity
JAGSNPHARM